Comparing Sentinel Node Biopsy to No Lymph Node Dissection in Early-Stage Endometrial Cancer Surgery
Led by Queensland Centre for Gynaecological Cancer · Updated on 2026-09-15
760
Participants Needed
23
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying endometrial cancer, the most common gynecological cancer, focusing on the value of sentinel node biopsy SNB compared to no retroperitoneal node dissection. The study aims to assess if SNB affects patient recovery, morbidity, quality of life, healthcare costs, and disease-free survival. This Phase III randomized clinical trial addresses ongoing controversy over lymph node dissections benefits and risks in early-stage endometrial cancer treatment.
Participants are randomly assigned to one of two groups one receiving total laparoscopic or robotic hysterectomy with bilateral salpingo-oophorectomy TH BSO combined with SNB using dye injections to identify sentinel lymph nodes, and the other receiving TH BSO without retroperitoneal node dissection. Some may omit ovary removal if under 45 with specific cancer features. The trial includes two stages the first with 444 patients focusing on recovery and quality of life, and the second with 316 patients evaluating disease-free survival over 4.5 years.
During the study, participants undergo surgery followed by multiple assessments including quality of life questionnaires, clinical evaluations for lymphoedema and adverse events, imaging, and molecular profiling. Researchers measure recovery at 12 months and disease-free survival at 4.5 years, along with cost-effectiveness, treatment requirements, and recurrence patterns. The total participation duration extends up to 4.5 years to monitor long-term outcomes and safety.
CONDITIONS
Brief Title
Sentinel Node Biopsy in Endometrial Cancer
Research Team
G
Grace Ngiam
S
Sara Baniahmadi
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Surgery with sentinel lymph node biopsy
Surgery without retroperitoneal node dissection
Systematic pelvic and para‑aortic lymphadenectomy (current‑care)
What it is
Surgical removal of the uterus, tubes, and ovaries with sentinel lymph node biopsy to assess lymph node involvement.
Surgical removal of the uterus, tubes, and ovaries without retroperitoneal lymph node dissection.
Systematic pelvic and para‑aortic lymphadenectomy is traditionally used for nodal staging in early‑stage endometrial cancer.
Role in the trial
Investigational surgical approach being evaluated in randomized assignment.
Active comparator arm in the randomization without nodal assessment.
Not part of this trial but reflects current surgical practice for nodal evaluation.
Primary use
Evaluate sentinel lymph node biopsy as a means to stage lymph nodes during surgery.
Perform standard surgery without assessing lymph nodes.
Conventional method for staging lymph node involvement using comprehensive dissection.
How it is done
Surgeon injects tracer dye around the tumour then removes sentinel lymph nodes during hysterectomy.
Surgeon performs hysterectomy and removal of ovaries and tubes without lymph node sampling.
Surgeon removes pelvic and para‑aortic lymph nodes systematically along with hysterectomy.
Evidence status
Early studies show sentinel node biopsy can accurately stage nodes with less morbidity.
Omitting nodal assessment avoids lymph node removal but does not provide staging information.
Systematic dissection has long been used to identify nodal metastasis and guide adjuvant therapy.
Important limitations
Technique and pathological ultrastaging protocols vary and lack universal standardization.
Cannot provide information about lymph node status, which may impact staging and treatment decisions.
Associated with higher operative time, blood loss, nerve and vessel injury, and long‑term lymphedema.
Patient impact
May reduce surgical morbidity compared with full lymphadenectomy while preserving staging capability.
Avoids lymph node removal and its risks but leaves uncertainty in staging that may affect treatment planning.
Provides detailed staging information but may lead to extended recovery and lymphedema affecting quality of life.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
FEMALE
Eligibility Criteria
You may qualify if you...
Female aged over 18 years
Histologically confirmed primary epithelial endometrial cancer or uterine carcinosarcoma
Clinically stage I disease confined to the uterus
ECOG performance status of 0 to 2
Eligible for laparoscopic or robotic surgery
No evidence of cancer spread outside the uterus by clinical exam or imaging
For women under 45 with Grade 1 cancer and less than 50% myometrial invasion, may retain ovaries
Negative pregnancy test within 30 days before surgery if pre-menopausal or less than 2 years post-menopause
You will not qualify if you...
Evidence of cancer spread outside the uterus including lymph nodes or other organs
Enlarged pelvic or aortic lymph nodes larger than 1 cm on imaging
Life expectancy less than 6 months
Absolute contraindications to radiotherapy or chemotherapy
Previous radiation treatment to the pelvis
Serious systemic disorders incompatible with the study
Unable to comply with follow-up or live far from study centers
Allergy to Indocyanine Green dye
Previous retroperitoneal surgery
Need for lymph node dissection
Other cancers within 5 years except certain skin or breast cancers
Uterine perforation during biopsy
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Short term around surgery time
Participants undergo laparoscopic or robotic hysterectomy with bilateral salpingo-oophorectomy, with or without sentinel node biopsy depending on random assignment.
Surgical procedure and hospital stay as needed
Follow-up
Duration - Up to 4.5 years after surgery
Participants are monitored through clinical assessments, imaging, quality of life questionnaires, and molecular tests to evaluate recovery, side effects, and cancer recurrence.
Regular follow-up visits and assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
5 Rs to Rescue Quality Improvement Program to Reduce Post-Surgery Deaths in Africa
A Multi-Center Trial Across Ethiopia, South Africa, Tanzania, and Uganda
Safety and Effectiveness of Indocyanine Green Imaging in Advanced Gastric Cancer Surgery Using 3D and Ultra High Resolution Laparoscopy
Using 68Ga-TCR-FAPI PETCT Imaging to Guide Surgery for Medullary Thyroid Cancer in Adults Aged 18 to 75
PINCER Platform Study for Solid Organ Cancers Providing Biosamples for Translational Research
Randomized Study Comparing Bariatric Surgery and Lifestyle Therapy for Severe NASH With Advanced Liver Fibrosis in Adults
Preventing Ovarian Cancer with Opportunistic Salpingectomy During Non-Gynecologic Surgery in Women 45 and Older
Using 3D Imaging Technology with Standard Scans to Guide Head and Neck Surgery
Evaluating Safety and Feasibility of Robotic Liver Surgery Compared to Other Liver Surgeries
Improving Surgical Recovery Programs for Adults with Low Health Literacy Using VISACT Strategy
Evaluating the S-PATH Clinical Decision Support System Compared to Usual Care
for Preoperative Blood Management in Surgery Patients
A Cluster-Randomized Crossover Trial
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer - ENDO-3: ANZGOG trial 1911/2020.